» Articles » PMID: 17000933

Medroxyprogesterone Acetate but Not Drospirenone Ablates the Protective Function of 17 Beta-estradiol in Aldosterone Salt-treated Rats

Overview
Journal Hypertension
Date 2006 Sep 27
PMID 17000933
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Controversial results obtained from human and animal studies on the prevention of heart disease by estrogens and progestins warrant a better understanding of nuclear hormone receptor function and interaction. To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity. The complex pattern of cardiovascular injury in ovariectomized Wistar rats induced by chronic aldosterone infusion plus a high-salt diet was significantly attenuated in sham-ovariectomized rats and by coadministration of 17beta-estradiol in ovariectomized animals after 8 weeks of continuous treatment. The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular osteopontin expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate. In contrast, drospirenone was either neutral or additive to 17beta-estradiol in protecting against aldosterone salt-induced cardiovascular injury and inflammation. The current results support the hypothesis of complex interactions among estrogen, progesterone, glucocorticoid, androgen, and mineralocorticoid receptor signaling in cardiovascular injury and inflammation. Novel progestins, such as drospirenone, confer superior effects compared with medroxyprogesterone acetate in a model of aldosterone-induced heart disease because of its antimineralocorticoid properties.

Citing Articles

Medroxyprogesterone opposes estradiol-induced renal damage in midlife ovariectomized Long Evans rats.

Zimmerman M, Ogola B, Wilkinson M, Visniauskas B, De Miguel C, Daniel J Menopause. 2020; 27(12):1411-1419.

PMID: 33109993 PMC: 7946153. DOI: 10.1097/GME.0000000000001675.


Levonorgestrel correlates with less weight gain than other progestins during hormonal replacement therapy in Turner Syndrome patients.

Mathez A, Monteagudo P, do Nascimento Verreschi I, Dias-da-Silva M Sci Rep. 2020; 10(1):8298.

PMID: 32427839 PMC: 7237408. DOI: 10.1038/s41598-020-64992-4.


Hormonal therapy with estradiol and drospirenone improves endothelium-dependent vasodilation in the coronary bed of ovariectomized spontaneously hypertensive rats.

Borgo M, Claudio E, Silva F, Romero W, Gouvea S, Moyses M Braz J Med Biol Res. 2015; 49(1):e4655.

PMID: 26577845 PMC: 4678653. DOI: 10.1590/1414-431X20154655.


Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.

Arias-Loza P, Muehlfelder M, Elmore S, Maronpot R, Hu K, Blode H Toxicol Pathol. 2009; 37(7):969-82.

PMID: 19841131 PMC: 2843525. DOI: 10.1177/0192623309350475.


Sex differences and central protective effect of 17beta-estradiol in the development of aldosterone/NaCl-induced hypertension.

Xue B, Badaue-Passos Jr D, Guo F, Gomez-Sanchez C, Hay M, Johnson A Am J Physiol Heart Circ Physiol. 2009; 296(5):H1577-85.

PMID: 19270192 PMC: 2685359. DOI: 10.1152/ajpheart.01255.2008.